Target
MPL
4 abstracts
Abstract
Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.Org: VCU Massey Comprehensive Cancer Center, Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust,
Abstract
Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET).Org: Sheba Medical Center–Tel HaShomer, Tel Aviv-Yafo, Royal Adelaide Hospital and SA Pathology,
Abstract
Outcomes of blast-phase MPN and JAK2, MPL, and CALR mutated de novo AML: A propensity score-adjusted cohort study.Org: Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Center, University of Minnesota Medical Center,
Abstract
EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.Org: MD Anderson Cancer Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, PharmaEssentia, Rutgers University, PharmaEssentia Japan KK,